Dr Liliana Galindo MD PhD

I am an Affiliated Assistant Professor of Psychiatry, CPFT's Medical Leader in Psychosis, and a consultant psychiatrist for the Trust's CAMEO early intervention service. My research over the past decade has focused on the study and integration of altered states of mind: Psychedelic Research (and other psychoactive substances) and Early Psychosis. I am interested in studying the psychoactive effects of substances, including therapeutic use, as well as understanding their effects on the development of psychopathology. I am founder and a Pl of the Cambridge Psychedelic Research Group, a multidisciplinary team composed of CPFT Cambridge University Hospitals and researchers from Cambridge University. Our research focuses on the safety and therapeutic potential of psychedelics in treating mental health conditions, as well as studying the mechanisms underlying their therapeutic action. I co-lead locally the Psychosis Risk Outcomes NETwork (ProNET), a global effort led by Yale University to improve prevention and treatment for clinical high-risk psychosis. I co-facilitate Conversations with Experts by Experience (CEbE) sessions led by people with lived experience of mental health challenges, for researchers and PhD students studying mental health conditions.